Myriad Genetics, Inc. (MYGN): Myriad’s lung cancer test meets primary endpoint … – Seeking Alpha

by lowes1 on September 25, 2013

Myriad Genetics, Inc. (MYGN): Myriad's lung cancer test meets primary endpoint
Seeking Alpha
Myriad Genetics' (MYGN) myPlan Lung Cancer test was more effective than conventional clinical parameters at predicting five-year disease survival in patients with early-stage, resectable lung adenocarcinoma. The results suggest the test could be help 

and more »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: